April 2017 Vol 3 No 2
Maryann Wahmann is the 2016 Hero of Hope Patient Award winner. Over 7 years, she had 7 colonoscopies, 7 endoscopies, and several wrong diagnoses before being diagnosed with carcinoid cancer, a type of neuroendocrine tumor (NET). Read More ›
By Jeff Pascal
Saying a few good words about cancer may seem a daunting task. However, lately it has occurred to me that my journey with cancer has some bright spots. It all began on March 17, 2014. The day you learn you might have cancer is a date you never forget. Read More ›
By Greg Kelly
Retiree Greg Kelly has a passion and affinity for model building. Read More ›
In March 2017, the FDA approved Kisqali (ribociclib), in combination with an aromatase inhibitor, for the first-line treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. Read More ›
In March 2017, the FDA approved Keytruda (pembrolizumab), anti-PD-1 immunotherapy, for the treatment of patients with classical Hodgkin lymphoma who are not responding to other therapy or whose disease (relapsed) returned after 3 or more therapies. Keytruda was previously approved for several cancers. Read More ›
In February 2017, the FDA approved the oral drug Revlimid (lenalidomide) for maintenance (continuing) therapy for patients with multiple myeloma who had autologous hematopoietic stem-cell transplant. Revlimid was previously approved for multiple myeloma and for other types of cancer. Read More ›
In January 2017, the FDA approved Imbruvica (ibrutinib) for the treatment of patients with marginal zone lymphoma who need systemic therapy and have received at least 1 previous anti-CD20-based therapy. Read More ›
In February 2017, the FDA approved Opdivo (nivolumab), anti-PD-1 immunotherapy, for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) whose disease progressed during or after platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Read More ›
In December 2016, the FDA approved Rubraca (rucaparib), a new oral PARP inhibitor, for the treatment of advanced ovarian cancer with a BRCA mutation (alteration) in patients who had received at least 2 chemotherapies. Read More ›
In February 2017, the FDA approved the oral drug Xermelo (telotristat ethyl) for the treatment of carcinoid syndrome diarrhea, in combination with a somatostatin analog (SSA), in adults with metastatic neuroendocrine tumors (NETs) whose condition is inadequately controlled by SSA therapy. Xermelo is the first oral therapy available for patients with carcinoid syndrome diarrhea in patients with NETs. Read More ›
Page 2 of 2
- 1
- 2